MyMD Pharmaceuticals, Inc. Stock Price, News & Analysis

MyMD Pharmaceuticals (Nasdaq: MYMD) announced that preclinical data for MYMD-1 has been accepted for presentation at the Society of Toxicology 2023 Annual Meeting. The study, focusing on MYMD-1's anti-inflammatory effects compared to Enbrel, will be presented on March 20, 2023, at 9:00 AM CT. MYMD-1 is an oral TNF-α inhibitor showing potential for treating rheumatoid arthritis, a condition affecting approximately 1.5 million people in the U.S. The company is also advancing MYMD-1 through a Phase 2 study for sarcopenia. MyMD is committed to innovating treatments for autoimmune and inflammatory diseases.

MyMD Pharmaceuticals (Nasdaq: MYMD) announced a securities purchase agreement to raise approximately $15 million in convertible preferred stock and warrants, expected to close on February 23, 2023. This financing will support the development of MYMD-1 for sarcopenia and rheumatoid arthritis. The preferred stock has a conversion price of $2.255 per share, a 10% premium to the closing share price on February 17, 2023. The offering is made under a previously filed shelf registration statement. MyMD aims to advance its clinical trials while continuing to explore MYMD-1’s applications in autoimmune diseases.

MyMD Pharmaceuticals (Nasdaq: MYMD) presented data at the 2022 British Society for Immunology Congress, highlighting MYMD-1^®, a selective TNF-α inhibitor. Preclinical studies demonstrated a 37% reduction in inflammation in a mouse model compared to 29% by etanercept (Enbrel^®). Clinical trials showed MYMD-1 was safe and well-tolerated at various doses. With its oral administration and ability to cross the blood-brain barrier, MYMD-1 may offer a new treatment avenue for rheumatoid arthritis and other autoimmune diseases.

MyMD Pharmaceuticals (Nasdaq: MYMD) is set to present late-breaking data on its drug candidate, MYMD-1, at the 2022 British Society for Immunology Congress in Liverpool, England, on December 6, 2022, at 6pm GMT. This oral TNF-α inhibitor shows promise in treating autoimmune diseases and may transform treatment strategies for conditions like rheumatoid arthritis. MYMD-1 is notable for its ability to orally administer therapy, crossing the blood-brain barrier while maintaining anti-inflammatory effects without immunosuppression.

MyMD Pharmaceuticals (NASDAQ: MYMD) announced the publication of positive results from a Phase 1 study of MYMD-1, an oral TNF-α inhibitor, in the journal Drug Research. The study demonstrated a favorable safety and tolerability profile without clinically relevant adverse events for single daily doses up to 450 mg and multiple daily doses of 600 mg. MYMD-1's oral formulation presents a significant advancement for treating autoimmune diseases, with ongoing Phase 2 trials for sarcopenia and plans to evaluate it for rheumatoid arthritis. Results are anticipated in Q4 2022.

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) announced progress in its Phase 2 clinical trial for MYMD-1®, an oral TNF-alpha inhibitor targeting chronic inflammation from sarcopenia and frailty. The trial has completed dosing for the second patient cohort, with no safety or toxicity issues reported. The Safety Review Committee unanimously approved escalating to the next dose, and enrollment for the next cohort will begin. Efficacy data is anticipated in Q4 2022.

MyMD Pharmaceuticals announced the European Patent Office's decision to grant patent claims for its Supera-CBD™ compound, recognizing it as a new molecular entity. This development demonstrates Supera-CBD™'s potential in treating pain and anxiety by selectively binding to the CB2 receptor. The ongoing clinical trial for MYMD-1, an oral TNF-α inhibitor aimed at reducing chronic inflammation, adds to MyMD's advancements in drug development, with positive progress noted in the trial's dosing. The company’s patent portfolio continues to expand globally.

MyMD Pharmaceuticals (MYMD) announced the publication of a pre-clinical study of its oral TNF-α inhibitor, MYMD-1, in the Journal of Gerontology. The study showed that MYMD-1 significantly outperformed rapamycin, demonstrating four-fold better results in delaying aging and extending lifespan in mice treated at the equivalent of 60 human years. The research indicated improvements in health span characteristics, including muscle strength and reduced frailty progression. MYMD-1 is currently in a Phase 2 study targeting sarcopenia and frailty.

MyMD Pharmaceuticals has announced progress in its Phase 2 clinical trial for MYMD-1, targeting aging-related sarcopenia. Patient enrollment for the next dose has begun after the Safety Review Committee confirmed no safety issues in the prior cohort. The trial aims to demonstrate reduced levels of TNF-alpha in patients aged 65 and over. The market opportunity is significant, with potential revenues exceeding $600 billion by 2025, as no FDA-approved drugs currently exist for treating aging disorders.